Makful 250 mg Injection 5 ml belongs to the class of estrogen blockers used to treat breast cancer in postmenopausal women. Breast cancer is a type of cancer that develops when the breast cells begin to grow abnormally.

Makful 250 mg Injection 5 ml contains Fulvestrant, which works by inhibiting some of the actions of estrogen (female sex hormone which may help cancer cells grow in women with breast cancer) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.

Makful 250 mg Injection 5 ml will be administered by a healthcare professional; do not self-administer. In some cases, Makful 250 mg Injection 5 ml may cause certain common side effects such as injection site reactions like pain and/or inflammation, weakness, nausea, tiredness, headache or joint and musculoskeletal pain. Most of these side effects of Makful 250 mg Injection 5 ml do not require medical attention and gradually resolve over time. However, if these side effects persist or worsen, please consult your doctor.

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Makful 250 mg Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Makful 250 mg Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Makful 250 mg Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Makful 250 mg Injection 5 ml.

Makful 250 mg Injection 5 ml is used in the treatment of Breast cancer in postmenopausal women. The detailed uses of Makful 250 mg Injection 5 ml are as follows:

• Treatment of breast cancer: Makful 250 mg Injection 5 ml is used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer in postmenopausal women.
• Treatment of progressed cancer: Makful 250 mg Injection 5 ml is prescribed when the cancer has progressed following prior endocrine therapy.

• Your doctor will decide the dosage and timing of Makful 250 mg Injection 5 ml based on the stage of cancer and your body’s response to the treatment. Usually, it is given every two weeks for the first three doses, then once monthly.
• Makful 250 mg Injection 5 ml will be administered by a doctor or nurse in a medical facility.
• Do not self-administer.

Makful 250 mg Injection 5 ml contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Makful 250 mg Injection 5 ml may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).

If you are allergic to Fulvestrant or any other medicines, please tell your doctor. Makful 250 mg Injection 5 ml is not recommended for pregnant women as it may harm an unborn baby. Using effective contraception while being treated with Makful 250 mg Injection 5 ml and for two years after the last dose is advised. Makful 250 mg Injection 5 ml is contraindicated for use during lactation. Avoid alcohol consumption while receiving Makful 250 mg Injection 5 ml. Avoid driving or operating machinery if you feel tired or weak after receiving Makful 250 mg Injection 5 ml.